Sen. Elissa Slotkin, D-Mich., remained silent Friday when asked about previous statements she made suggesting that government officials should be prepared to push back on President Donald Trump if he ordered the military to fire on civilians.

Slotkin and other Democrats now face a reversal of those worries as the country reels from a shooting Wednesday that left one National Guard member dead and another in critical condition in Washington. 

Her office did not respond to multiple requests for comment.

VIRGINIA DEM SAYS TRUMP ADMIN HAS 'TAKEN ITS EYE OFF THE BALL' ON PUBLIC SAFETY AMID NATIONAL GUARD SHOOTING

Slotkin’s alarm about the National Guard and other federal troops originally stemmed from comments Trump allegedly made to former Secretary of Defense Mark Esper under his first term.

"The president in the last administration asked then-secretary (Mark) Esper to send in the 82 Airborne into Washington, D.C. to try to quell peaceful protests here in the city. And he said, if necessary, can’t you just ‘shoot at their legs?’" Slotkin said in a January committee hearing. 

Esper recorded those quotes as part of the administration's considerations of how to respond to protests over the death of George Floyd. Floyd's 2020 killing by a Minneapolis police officer sparked nationwide protests and ignited the Black Lives Matter movement. 

The quotes were included in Esper’s book, "A Sacred Oath" — a highly critical memoir of the first Trump Administration.

Trump has denied ever making the statement.

FORMER ARMY CAPTAIN WARNS DEMS’ ‘UNPATRIOTIC’ VIDEO TELLING TROOPS TO DEFY ORDERS COULD SPARK CHAOS

The statements Trump allegedly made to Esper — and other questions about Trump’s use of federal troops — prompted Slotkin and six other Democrat lawmakers to release a video earlier in November, calling for service members to "not give up the ship." In it, they urged members of the military and intelligence community to disregard illegal orders.

"The threats to our Constitution aren’t just coming from abroad but from right here at home," the lawmakers said in the video. "Our laws are clear: You can refuse illegal orders. You must refuse illegal orders. No one has to carry out orders that violate the law or our Constitution." 

When asked what they meant by illegal acts, several lawmakers pointed to Trump’s comments about shooting protesters in the legs, an act that they said would go against the Uniform Code of Military Justice. 

Besides Slotkin, Sen. Mark Kelly, D-Ariz., Rep. Jason Crow, D-Colo., Rep. Chris Deluzio, D-Pa., Rep. Chrissy Houlahan, D-Pa., and Rep. Maggie Goodlander, D-N.H., also appeared in the video. 

DEMOCRATIC SENATOR 'NOT AWARE' IF TRUMP GAVE ANY ILLEGAL MILITARY ORDERS AMID VIDEO CONTROVERSY

Wednesday's shooter’s motives remain unclear. 

The FBI has identified him as 29-year-old Afghan national Rahmanullah Lakanwal, a former member of a counterterrorism team in Afghanistan. He is in custody and faces first-degree murder charges.

The bureau has described his attack as targeted and are investigating it as an act of terrorism. 

A potential cure for type 1 diabetes has been identified by scientists in a new mouse study.

In an animal study, researchers at Stanford School of Medicine discovered that resetting the immune system in diabetic mice and creating new insulin-making cells reversed the disease in 100% of cases, according to a Stanford press release.

The researchers took a group of 19 pre-diabetic mice and gave them a non-toxic "conditioning" treatment that included low levels of radiation and special antibodies that reduce certain immune cells called T-cells, according to the study release.

HOW TO REVERSE PREDIABETES BEFORE IT LEADS TO TYPE 2 DIABETES

The goal was to make the mice’s immune systems less reactive so that the scientists could test new therapies more effectively.

The mice then received stem cell transplantation using the bone marrow cells of other mice, as well as donor islet cells (insulin-making) cells.

The researchers’ goal was to create a "mixed chimerism" — an environment where the mouse has both its own cells and donor immune cells.

This method prevented the development of diabetes in all 19 pre-diabetic mice, as published in the Journal of Clinical Investigation.

The researchers also studied nine mice that had long-standing type 1 diabetes. All nine of the mice were cured by the combined stem cell and islet transplantation.

The results did not indicate any major side effects or immunity depletion, the scientists noted.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Although this study was only done in mice and required some radiation, which could be limiting in future research, the experts shared their optimism that the treatment could eventually be applied to humans.

In addition to diabetes, this "gentler pre-conditioning approach" could make stem cell transplants a "viable treatment for autoimmune disease such as rheumatoid arthritis and lupus, and non-cancerous blood conditions like sickle cell anemia," the researchers wrote.

"The key steps in our study — which resulted in animals with a hybrid immune system containing cells from both the donor and the recipient — are already being used in the clinic for other conditions," study co-author Seung K. Kim, M.D., Ph.D., the KM Mulberry Professor and a professor of developmental biology, gerontology, endocrinology and metabolism at Stanford University, wrote in a statement.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"We believe this approach will be transformative for people with type 1 diabetes or other autoimmune diseases, as well as for those who need solid organ transplants."

Fox News senior medical analyst Dr. Marc Siegel commented on these findings in an interview with Fox News Digital, noting that although it is "preliminary work," it could show promise for humans.

CLICK HERE FOR MORE HEALTH STORIES

"This is a feasible approach and can be translated into human treatment, but will need to be modified via genetic analysis and artificial intelligence for a personalized approach to autoimmunity, which causes type 1 diabetes," he said. "It's not one-size-fits-all."